A B S T R A C T The presence of specific Factor VIII/ von Willebrand factor (FVIII/vWF) 
INTRODUCTION
Human Factor VIII/von Willebrand factor (FVIII/ vWF)1 is a plasma glycoprotein which has a mol wt 1.1 x 106 and is composed of an undetermined number of 200,000-dalton subunits linked covalently by disulfide bonds (1, 2) . This glycoprotein has two Dr. McKee is an Investigator ofthe Howard Hughes Medical Institute. 656 distinct biological activities: one being procoagulant activity (Factor VIII) which can specifically correct the blood coagulation defect of classical hemophilia patients; the other being platelet-aggregating activity, also known as von Willebrand factor activity, which is important for platelet plug formation at the site of vascular injury (3, 4) . In von Willebrand's disease, a marked decrease in platelet-aggregating activity results in easy bruising, hemorrhage from mucous membranes, and a prolonged bleeding time (5); these defects can usually be corrected by administration of human FVIII/vWF concentrates. In 1973, Howard et al. (6) reported that the in vitro addition of an antibiotic, ristocetin, to normal platelet-rich plasma caused platelets to clump. In contrast, the addition of ristocetin promoted little or no clumping activity in the majority of platelet-rich plasma samples from patients with von Willebrand's disease (6) . These observations were used to develop methods for quantitating plasma von Willebrand factor activity by measuring the rate or degree of aggregation of washed, normal human platelets to which aliquots of test plasma and ristocetin were added (7) . At present, the mechanism by which FVIII/vWF protein interacts with platelets to cause aggregate formation in vivo or in vitro is still unknown. Nevertheless, immunofluorescent techniques (8) and the recovery of FVIII/ vWF activity from platelet membrane (9) or platelet aggregates (10, 11) suggest that FVIII/vWF binds to human platelets. Such results prompted the hypothesis that binding of FVIII/vWF to specific sites on human platelets may be required for normal platelet aggregation to occur.
We now report evidence for the presence of specific binding sites for FVIII/vWF on human platelets, using a competitive, radiolabeled ligand binding assay. Some of the characteristics of these binding sites are also described. 6.8) . Residual ammonium sulfate in the precipitate was removed by dialysis at 4°C against the same buffer. The purified FVIII/vWF was stored at 40C in a final conceentration of 1.5-2.5 mg/ml. The purity ofthe final prodluet was anialyzed by electrophoresis on sodium dodecyl sulfate-6M urea-5% polyacrylamide gels before and after reduction by 83-mercaptoethanol (12, 13) . Radioioditnaition of FVIII/vcW'F. Highly purified FVIII/ vWF was labeled with 125j by the Sepharose 4B-lactoperoxidase method of David and Reisfeld (14) . The iodination was performed by mixing the solutions in the following sequence: 50 plI of Na125I (1 mCi/0.1 ml) in 0.1 N NaOH; 50 ,ul of 0.1 N HCl; 10 pAl of 1.1 mM KI; 100 ,lA of 50% (vol/vol) Sepharose 4B-lactoperoxidase suspended in 0.01 M sodium phosphate, 0.1 M NaCl buffer (pH 7.0); and 0.5 ml of' FVIII/vWF (2 mg/ml) dissolved in 0.01 M sodiuim phosphate, 0.1 M NaCl buffer (pH 7.0). The reaction was initiated by adding 5 ,ul of 6.7 mM H202; the solution was then left at room temperature and stirred frequently for the next 30 min. The reaction was quenched by adding 15 ,lI of 2.5 M NaN3. The solution was centrifuged, and the supernate was applied to a 1 x 15-cm Sephadex G-25 column which had been equilibrated with 0.025 M cacodylate, 0.15 M NaCl buffer (pH 6.8), and pretreated with 2 ml of 1% BSA dissolved in the same buffer. The column was eluted with 0.025 M cacodylate, 0.15 M NaCl buffer, and 0.5-ml aliquots were collected and counted in a gamma couinter (model 4000, Beckman Instruments, Inc., Fullerton, Calif.). Usually, two peaks were obtained: the first peak was iodinated FVIII/vWF, and the second was free 1251. The fractions of the first peak which contained the iodinated FVIII/vWF were pooled, andl the specific activity of the preparation was determined by measuring the radioactivity and the protein concentration (15) . This iodination procedure routinely yielded 125I-FVIII/vWF with a specific radioactivity of 0.3-0.4 ,Cilt,g. The plateletaggregating activity of the iodinated FVIII/vWF was assayed by the ristocetin-induced platelet aggregation method as described previously (16) .
Preparation of wvashed platelets, erythrocytes (RBC), and polyrnorphonuclear letukocyte (PMN). With a two-syringe technique, 18 ml ofvenous blood were drawn into 2 ml of3.8% sodium citrate. After immediate mixing, the blood sample was centrifuged at 250 g for 10 min at room temperature to obtain platelet-rich plasma and sedimented RBC. The RBC were saved while the plasma was further centrifuged at 6,000 g for 10 min at room temperature to sediment the platelets. The platelet pellet was washed five times by resuspending it in 16 ml of' 0.025 M Tris-HCl, 0.15 M NaCl, 0.01 M EDTA (pH 7.4), and then centrifuging at 6,000 g for 10 min at room temperature. After the last wash, the platelets were resuspended in 0.025 M Tris-HCl, 0.15 M NaCl, 0.1% BSA (pH 7.4). The RBC were washed in a similar fashion except that the centrifugation was carried out at 300g. To each milliliter of packed RBC, 8 ml of washing buffer was added.
PMN were prepared according to the method of B0yum (17). 20 ml of venous blood was drawn into a heparinized syringe which contained 5 ml of plasma gel. After mixing the blood with the gel, the syringe was placed vertically in an incubator at 370C. RBC sedimented in the syringe by 60 min. The PMN-rich plasma was collected from the top of the syringe and layered on top of a tube containing 12 ml of the lymphocyte separation medium. The PMN pellet was collected by centrifuging at 400 g for 30 min at room temperature, washed twice in Hank's balanced salt solution (pH 7.4), and resuspended in the same solution. The concentration of cells in the suspension was determined with a hemacytometer and phase-contrast microscopy and adjusted to the final desired concentration with an appropriate volume of the same buffer.
Factor VIII/von WVillebrand Factor Specific Binding Sites 657 (3 x 106 cells) were incubated with 0.1 ,ug of 125I-FVIII/vWF (_15,000 cpm) at specified concentrations of ristocetin. The key to the concentration of ristocetin used for each incubation is as follows: (0), 1.5 mg/ml; (-), 1.0 mg/ml; (E), 0.8 mg/ml; (-), 0.6 mg/ml; (A), 0.3 mg/ml; (A), 0.1 mg/ml; (), 0 mg/ml. was incubated with increasing amounts of 125I-FVIII/ vWF at two concentrations of ristocetin (1 or 0.5 mg/ ml). The results are illustrated in Fig. 3 Fig. 4A shows that the apparent dissociation constant (Kd) is 0.46 and 0.5 nM at concentrations of ristocetin of 1.0 and 0.5 mg/ml, respectively. The total concentrations of binding sites deter- mined from the intercepts of the abscissa were 0.52 nM (31,000 sites per platelet) and 0.23 nM (13,700 sites per platelet), respectively; these results are calculated assuming univalency for the FVIII/vWF molecule of 1.1 x 106 daltons. In Fig. 4B , these values for the binding affinity and receptor concentration were validated by Scatchard analysis of the data obtained from the competition study illustrated in Fig. 5 . These results confirmed that a significantly greater number of total specific binding sites are present at the higher ristocetin concentration, but that the binding affinities are about the same at either concentration of ristocetin.
Specificity of the 1251-FVIIIIvWF binding to platelets. The specificity of FVIII/vWF binding sites on platelets was studied by incubating 0.1 ,ug of 1251_ FVIII/vWF with various concentrations of unlabeled human FVIII/vWF, thrombin, fibrinogen, a2-macroglobulin, bovine FVIII/vWF, equine collagen, or RC-60. Fig. 5 shows that only unlabeled human or bovine FVIII/vWF can compete with 125I-FVIII/vWF for the binding, and that bovine FVIII/vWF is somewhat less potent in competing for binding than human FVIII/vWF. Human thrombin, fibrinogen, a2-macroglobulin, equine collagen, and RC-60, even at very high concentrations (at least 2-800-fold molar excess of 1251-FVIII/vWF added), could not compete, despite the fact that most of these proteins are either known or believed to interact with platelets; some induce aggregation and(or) release cytoplasmic granules (20, 21) .
The binding of 125I-FVIII/vWF to human RBC or PMN in the presence of ristocetin was also tested. (22) (23) (24) . The results shown in Table II (5 x 106) and 125I-FVIII/vWF (0.1 .g/incubation) with specified concentrations of unlabeled proteins (0-50 ,g); B defines the amount of '251-FVIII/vWF which specifically binds to platelets and cannot be displaced by amounts of unlabeled FVIII/vWF as specified on the abscissa. Bo is the total specific binding which is the difference in counts per minute between platelet pellets from incubations with and without 50 ,ug of unlabeled FVIII/vWF. B/Bo gives the ratio of total specific binding which remains. Two concentrations ofristocetin were used: (0), 0.5 mg/ml and (0, A), 1.0 mg/ml. were used. In contrast, EGTA was highly inhibitory. At a concentration of 2 mM, EGTA inhibited 86% of 125I-FVIII/vWF binding. The inhibitory effect of EGTA cannot be attributed to its Ca++ chelating ability because EDTA, Ca++, and Mg++ do not affect binding. Thus, the inhibitory effect of EGTA must be a result of other of its physiochemical properties.
Effect of pH on the binding of 125I-FVIII/vWF to platelets. This study was performed in 0.025 M Trismaleate-NaOH, 0.15 M NaCl buffers ranging from pH The technique for determining specific binding is described in Methods. The pH of all incubations was 7.4. Each specificbinding value is the mean of duplicate experiments, the variation between duplicates is <4%.
5.3 to pH 9.0. Fig. 6 shows that maximum binding occurs between pH 7.0 and pH 7.5. On either side of this range, binding is reduced drastically. These values of optimal pH for the binding of 1251-FVIII/vWF to platelets in the presence of ristocetin are essentially the same as reported for FVIII/vWF-dependent, ristocetin-induced platelet aggregation (25, 26) . Dissociation of specifically bound 125I-FVIII/vIVF from platelets. The dissociation of specifically bound 1251-FVIII/vWF from platelets was investigated at room temperature by adding a chase quantity of unlabeled FVIII/vWF into incubations in which binding had reached equilibrium. Fig. 7 shows that the dissociation of bound 1251-FVIII/vWF is very slow. Initially a relatively rapid dissociation is observed, but then the dissociation gradually ceases at longer incubation times. Because of the loss of reversibility of the binding after long-term incubation, kinetic analysis of the dissociation of bound 1251-FVIII/vWF was not practical. Similar phenomena have been observed previously with peptide hormone receptors for prolactin (27) and gonadotropin (28) . Fig. 7 shows that if the ristocetin concentration is reduced to 0.1 mg/ml at zero time, the amount of 1251-FVIII/vWF becoming dissociated is increased. At 6 h only 45% of that bound at zero time remained on fresh, washed platelets; beyond 6 h, no further dissociation occurred. Fig. 7 also shows that if formalin-fixed platelets are used and the ristocetin concentration is reduced to 0.1 mg/ml at zero time, -90% of the bound 1251-FVIII/vWF becomes dissociated by 6 h.
Binding of 125I-FVIIIIvWF to platelets treated with chymotrypsin. It has been demonstrated that platelet membrane proteins are hydrolyzed during incubation with trypsin (29) or chymotrypsin (30) . The binding sites of FVIII/vWF are presumed to be on the membrane of platelets because of the high molecular weight of FVIII/vWF. If the membrane binding sites for FVIII/vWF are protein, they might be susceptible to enzymatic digestion and, therefore, the specific binding of 1251-FVIII/vWF should become diminished. This hypothesis is supported by this study. Table III shows that the specific binding of 1251-FVIII/vWF to platelets did decrease progressively as platelets were preincubated with increasing concentrations of achymotrypsin.
DISCUSSION
Our studies demonstrate that high affinity specific binding sites for FVIII/vWF exist on human plate-E 0. Recently Jenkins et al. (30) reported that membrane glycoprotein I of human platelets is involved in FVIII/vWF-dependent, ristocetin-induced platelet aggregation. Furthermore, Nachman et al. (35) demonstrated that ristocetin-induced platelet aggregation was inhibited by rabbit antiserum to glycoprotein I. Okumura and Jamieson (36) reported that another glycoprotein (glycocalicin), which functions as a thrombin receptor in the exterior coat of platelets, inhibited ristocetin-induced platelet aggregation. These authors further demonstrated that glycocalicin is immunologically and electrophoretically similar to membrane glycoprotein I of platelets (37, 38) . Thus the possibility that FVIII/vWF shares the same receptor 
